ESC 365 - Ertugliflozin and the VERTIS program – What have we learned to date?

ESC Premium Access

Ertugliflozin and the VERTIS program – What have we learned to date?

Session: Evidence-based treatment of patients with SGLT-2is - What do we know and what is missing?

Topic: Diabetes and the Heart

Speaker: Professor L. Leiter (Toronto, CA)

Sponsored by MSD

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Professor Lawrence Leiter

University of Toronto, Toronto (Canada)

19 presentations

0 follower

6 more presentations in this session

Welcome and opening remarks

Speaker: Professor D. McGuire (Dallas, US)

What is the role for SGLT2is for patients with heart failure? A cardiologist’s view

Speaker: Professor G. Filippatos (Athens, GR)

SGLT2 Inhibitors - Diabetes or renal drugs?

Speaker: Professor P. Groop (Helsinki, FI)

Questions and answers

Bringing forward the future of SGLT2 inhibitors in the treatment of patients with diabetes and cardiovascular disease - A roundtable dscussion

Speaker: Professor D. McGuire (Dallas, US) Professor L. Leiter (Toronto, CA) Professor G. Filippatos (Athens, GR) Professor P. Groop (Helsinki, FI)

Access the full session

Evidence-based treatment of patients with SGLT-2is - What do we know and what is missing?

Speakers: Professor L. Leiter, Professor D. McGuire, Professor G. Filippatos, Professor P. Groop, Professor D. McGuire...

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources